FR2692575B1
(fr)
*
|
1992-06-23 |
1995-06-30 |
Sanofi Elf |
Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
|
FR2713224B1
(fr)
*
|
1993-12-02 |
1996-03-01 |
Sanofi Sa |
N-pipéridino-3-pyrazolecarboxamide substitué.
|
FR2713225B1
(fr)
*
|
1993-12-02 |
1996-03-01 |
Sanofi Sa |
N-pipéridino-3-pyrazolecarboxamide substitué.
|
FR2714057B1
(fr)
*
|
1993-12-17 |
1996-03-08 |
Sanofi Elf |
Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
|
JPH10510512A
(ja)
*
|
1994-10-04 |
1998-10-13 |
藤沢薬品工業株式会社 |
尿素誘導体とacat阻害剤としての用途
|
FR2732967B1
(fr)
*
|
1995-04-11 |
1997-07-04 |
Sanofi Sa |
1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
|
FR2741621B1
(fr)
*
|
1995-11-23 |
1998-02-13 |
Sanofi Sa |
Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
|
FR2742148B1
(fr)
*
|
1995-12-08 |
1999-10-22 |
Sanofi Sa |
Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
|
FR2758723B1
(fr)
*
|
1997-01-28 |
1999-04-23 |
Sanofi Sa |
Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
|
DE19706903A1
(de)
|
1997-02-21 |
1998-08-27 |
Bayer Ag |
Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
|
JP2001516361A
(ja)
*
|
1997-03-18 |
2001-09-25 |
スミスクライン・ビーチャム・コーポレイション |
新規カンナビノイド受容体作動薬
|
FR2761266B1
(fr)
*
|
1997-03-28 |
1999-07-02 |
Sanofi Sa |
Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
|
US6630507B1
(en)
|
1998-04-21 |
2003-10-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cannabinoids as antioxidants and neuroprotectants
|
ATE247097T1
(de)
*
|
1998-05-04 |
2003-08-15 |
Univ Connecticut |
Analgetische und immunomodulierende cannabinoiden
|
US7589220B2
(en)
|
1998-06-09 |
2009-09-15 |
University Of Connecticut |
Inhibitors of the anandamide transporter
|
US7897598B2
(en)
|
1998-06-09 |
2011-03-01 |
Alexandros Makriyannis |
Inhibitors of the anandamide transporter
|
US7161016B1
(en)
|
1998-11-24 |
2007-01-09 |
University Of Connecticut |
Cannabimimetic lipid amides as useful medications
|
US7276613B1
(en)
|
1998-11-24 |
2007-10-02 |
University Of Connecticut |
Retro-anandamides, high affinity and stability cannabinoid receptor ligands
|
FR2789079B3
(fr)
|
1999-02-01 |
2001-03-02 |
Sanofi Synthelabo |
Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
|
US6274635B1
(en)
|
1999-03-22 |
2001-08-14 |
Immugen Pharmaceuticals Inc. |
Alkylated resorcinol derivatives for the treatment of immune diseases
|
US6566560B2
(en)
|
1999-03-22 |
2003-05-20 |
Immugen Pharmaceuticals, Inc. |
Resorcinolic compounds
|
CO5180550A1
(es)
|
1999-04-19 |
2002-07-30 |
Smithkline Beecham Corp |
Inhibidores de fab i
|
AR024158A1
(es)
|
1999-06-01 |
2002-09-04 |
Smithkline Beecham Corp |
Compuestos antibacterianos
|
CA2636755C
(en)
|
1999-08-03 |
2010-10-19 |
Ortho-Mcneil Pharmaceutical, Inc. |
Process for preparing 1,5-diaryl-3-substituted pyrazoles
|
FR2799124B1
(fr)
*
|
1999-10-01 |
2004-08-13 |
Sanofi Synthelabo |
Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
|
CA2387016C
(en)
*
|
1999-10-08 |
2010-09-28 |
William H. Miller |
Acrylamide derivatives as fab i inhibitors
|
US6762201B1
(en)
|
1999-10-08 |
2004-07-13 |
Affinium Pharmaceuticals, Inc. |
Fab I inhibitors
|
US6730684B1
(en)
|
1999-10-08 |
2004-05-04 |
Affinium Pharmaceuticals, Inc. |
Fab I inhibitors
|
DE60029235T2
(de)
*
|
1999-10-08 |
2007-06-14 |
Affinium Pharmaceuticals, Inc., Toronto |
Fab-i-hemmer
|
CA2286442A1
(en)
*
|
1999-10-15 |
2001-04-15 |
Universite De Montreal |
Compositions for increasing the concentration of cannabinoids as vasodilators and cardioprotectors againts ischaemia
|
MXPA02005103A
(es)
|
1999-10-18 |
2003-09-25 |
Alexipharma Inc |
Ligandos selectivos del receptor de canabinoide (cb2) perifericos.
|
US7119108B1
(en)
|
1999-10-18 |
2006-10-10 |
University Of Connecticut |
Pyrazole derivatives as cannabinoid receptor antagonists
|
US6943266B1
(en)
*
|
1999-10-18 |
2005-09-13 |
University Of Connecticut |
Bicyclic cannabinoid agonists for the cannabinoid receptor
|
US7741365B2
(en)
|
1999-10-18 |
2010-06-22 |
University Of Connecticut |
Peripheral cannabinoid receptor (CB2) selective ligands
|
US7393842B2
(en)
|
2001-08-31 |
2008-07-01 |
University Of Connecticut |
Pyrazole analogs acting on cannabinoid receptors
|
US8084467B2
(en)
|
1999-10-18 |
2011-12-27 |
University Of Connecticut |
Pyrazole derivatives as cannabinoid receptor antagonists
|
US6900236B1
(en)
|
1999-10-18 |
2005-05-31 |
University Of Connecticut |
Cannabimimetic indole derivatives
|
EP1224173B1
(de)
*
|
1999-10-18 |
2005-10-12 |
The University Of Connecticut |
Pyrazol-derivate als cannabinoidrezeptor-antagonisten
|
FR2800372B1
(fr)
|
1999-11-03 |
2001-12-07 |
Sanofi Synthelabo |
Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
|
FR2800375B1
(fr)
|
1999-11-03 |
2004-07-23 |
Sanofi Synthelabo |
Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
|
FR2804604B1
(fr)
*
|
2000-02-09 |
2005-05-27 |
Sanofi Synthelabo |
Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
|
RU2245878C2
(ru)
*
|
2000-03-23 |
2005-02-10 |
Солвей Фармасьютикалс Б.В. |
Производные 4,5-дигидро-1н-пиразола, обладающие cb1-антагонистической активностью
|
US6492385B2
(en)
|
2000-08-18 |
2002-12-10 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
AU2001282875A1
(en)
|
2000-08-21 |
2002-03-04 |
Pharmacia And Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
WO2002015662A2
(en)
|
2000-08-21 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
|
US6541510B2
(en)
*
|
2000-09-28 |
2003-04-01 |
Immugen Pharmaceuticals, Inc. |
Antiviral methods and compounds
|
WO2002026224A2
(en)
*
|
2000-09-28 |
2002-04-04 |
Immugen Pharmaceuticals, Inc. |
Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
|
US20020091114A1
(en)
|
2000-10-04 |
2002-07-11 |
Odile Piot-Grosjean |
Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
|
EP1361876A4
(de)
|
2001-01-26 |
2004-03-31 |
Univ Connecticut |
Neue cannabimimetische liganden
|
US7173027B2
(en)
|
2001-01-29 |
2007-02-06 |
University Of Connecticut |
Receptor selective cannabimimetic aminoalkylindoles
|
US7067539B2
(en)
*
|
2001-02-08 |
2006-06-27 |
Schering Corporation |
Cannabinoid receptor ligands
|
PL363751A1
(en)
*
|
2001-03-22 |
2004-11-29 |
Solvay Pharmaceuticals B.V. |
4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
|
DK1560584T3
(da)
*
|
2001-04-06 |
2009-05-18 |
Affinium Pharm Inc |
Fab I inhibitorer
|
CA2452881C
(en)
*
|
2001-07-13 |
2012-03-06 |
University Of Connecticut |
Novel bicyclic and tricyclic cannabinoids
|
AU2002319627A1
(en)
|
2001-07-20 |
2003-03-03 |
Merck And Co., Inc. |
Substituted imidazoles as cannabinoid receptor modulators
|
BR0211705A
(pt)
*
|
2001-08-06 |
2004-09-28 |
Astrazeneca Ab |
Processo para a preparação de uma dispersão estável de partìculas sólidas em um meio aquoso, dispersão estável aquosa, partìcula sólida, composição farmacêutica, método para a inibição do amadurecimento de ostwald em uma dispersão de partìculas sólidas substancialmente insolúveis em água em um meio aquoso, e, uso de um inibidor
|
JP2005504058A
(ja)
|
2001-08-24 |
2005-02-10 |
ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー |
疾患の治療のための置換ヘテロアリール−7−アザ[2.2.1]ビシクロヘプタン
|
AU2002331766A1
(en)
*
|
2001-08-31 |
2003-03-18 |
University Of Connecticut |
Novel pyrazole analogs acting on cannabinoid receptors
|
CN1529595A
(zh)
*
|
2001-09-21 |
2004-09-15 |
������ҩ������˾ |
具有效cb1-拮抗活性的4,5-2氢-1h-吡唑衍生物
|
TWI231757B
(en)
|
2001-09-21 |
2005-05-01 |
Solvay Pharm Bv |
1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
|
RU2299199C2
(ru)
*
|
2001-09-21 |
2007-05-20 |
Солвей Фармасьютикалс Б.В. |
Новые производные 4,5-дигидро-1h-пиразола, имеющие cb1-антагонистическую активность
|
UY27450A1
(es)
*
|
2001-09-24 |
2003-04-30 |
Bayer Corp |
Preparación y uso de derivados de imidazol para el tratamiento de la obesidad
|
JP2005510492A
(ja)
|
2001-10-26 |
2005-04-21 |
ユニバーシティ オブ コネチカット |
新規な種類の効力のあるカンナビミメティックリガンド
|
FR2831883B1
(fr)
*
|
2001-11-08 |
2004-07-23 |
Sanofi Synthelabo |
Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
MXPA04004464A
(es)
*
|
2001-11-08 |
2004-08-11 |
Upjohn Co |
Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
|
US20040171613A1
(en)
*
|
2001-12-27 |
2004-09-02 |
Japan Tobacco Inc. |
Therapeutic agent for non-immediate type allergic diseases
|
US20040248956A1
(en)
*
|
2002-01-29 |
2004-12-09 |
Hagmann William K |
Substituted imidazoles as cannabinoid receptor modulators
|
WO2003075917A1
(en)
*
|
2002-03-08 |
2003-09-18 |
Signal Pharmaceuticals, Inc. |
Combination therapy for treating, preventing or managing proliferative disorders and cancers
|
WO2003077847A2
(en)
*
|
2002-03-12 |
2003-09-25 |
Merck & Co., Inc. |
Substituted amides
|
CN1652766A
(zh)
*
|
2002-03-18 |
2005-08-10 |
免疫力药品有限公司 |
间苯二酚和大麻素的局部制剂及其施用方法
|
AR038966A1
(es)
*
|
2002-03-18 |
2005-02-02 |
Solvay Pharm Bv |
Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
|
US7423067B2
(en)
*
|
2002-03-26 |
2008-09-09 |
Merck & Co., Inc. |
Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists
|
AU2003225964B2
(en)
*
|
2002-03-28 |
2008-11-20 |
Merck Sharp & Dohme Corp. |
Substituted 2,3-diphenyl pyridines
|
JP4459629B2
(ja)
*
|
2002-04-12 |
2010-04-28 |
メルク エンド カムパニー インコーポレーテッド |
二環式アミド
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
US6932971B2
(en)
|
2002-07-18 |
2005-08-23 |
Cytos Biotechnology Ag |
Hapten-carrier conjugates and uses thereof
|
GB0216700D0
(en)
*
|
2002-07-18 |
2002-08-28 |
Astrazeneca Ab |
Process
|
KR100741231B1
(ko)
|
2002-07-29 |
2007-07-19 |
에프. 호프만-라 로슈 아게 |
신규 벤조다이옥솔
|
EP1542999A1
(de)
|
2002-08-01 |
2005-06-22 |
Pharmacia & Upjohn Company LLC |
1h-pyrazol- und 1h-pyrrol-azabicyclische verbindungen mit alpha-7-nachr-aktivität
|
UY27939A1
(es)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
Compuestos
|
CA2496097A1
(en)
|
2002-08-23 |
2004-03-04 |
University Of Connecticut |
Keto cannabinoids with therapeutic indications
|
US7319110B2
(en)
*
|
2002-09-19 |
2008-01-15 |
Solvay Pharmaceuticals B.V. |
1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity
|
WO2004029204A2
(en)
|
2002-09-27 |
2004-04-08 |
Merck & Co., Inc. |
Substituted pyrimidines
|
EP1556373A1
(de)
*
|
2002-10-18 |
2005-07-27 |
Pfizer Products Inc. |
Cannabinoid rezeptorenliganden und ihre verwendung
|
US7129239B2
(en)
*
|
2002-10-28 |
2006-10-31 |
Pfizer Inc. |
Purine compounds and uses thereof
|
JP4859460B2
(ja)
*
|
2002-12-06 |
2012-01-25 |
アフィニウム ファーマシューティカルズ, インク. |
ヘテロ環化合物、その製造方法および治療におけるその使用
|
US7247628B2
(en)
*
|
2002-12-12 |
2007-07-24 |
Pfizer, Inc. |
Cannabinoid receptor ligands and uses thereof
|
GB0230088D0
(en)
*
|
2002-12-24 |
2003-01-29 |
Astrazeneca Ab |
Therapeutic agents
|
GB0230087D0
(en)
*
|
2002-12-24 |
2003-01-29 |
Astrazeneca Ab |
Therapeutic agents
|
WO2004060870A1
(en)
|
2003-01-02 |
2004-07-22 |
F. Hoffmann-La Roche Ag |
Novel cb 1 receptour inverse agonists
|
ATE400571T1
(de)
|
2003-01-02 |
2008-07-15 |
Hoffmann La Roche |
Pyrrolyl-thiazole und ihre verwendung als inverse agonisten des cb 1 rezeptors
|
ES2295816T3
(es)
|
2003-01-14 |
2008-04-16 |
Arena Pharmaceuticals, Inc. |
Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
GB0302673D0
(en)
*
|
2003-02-06 |
2003-03-12 |
Astrazeneca Ab |
Pharmaceutical formulations
|
US7329658B2
(en)
*
|
2003-02-06 |
2008-02-12 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
GB0302671D0
(en)
*
|
2003-02-06 |
2003-03-12 |
Astrazeneca Ab |
Pharmaceutical formulations
|
GB0302672D0
(en)
*
|
2003-02-06 |
2003-03-12 |
Astrazeneca Ab |
Pharmaceutical formulations
|
CA2515119A1
(en)
*
|
2003-02-07 |
2004-08-19 |
Daiichi Pharmaceutical Co., Ltd. |
Pyrazole derivative
|
US7176210B2
(en)
*
|
2003-02-10 |
2007-02-13 |
Pfizer Inc. |
Cannabinoid receptor ligands and uses thereof
|
CA2519429C
(en)
|
2003-03-17 |
2013-08-06 |
Affinium Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
|
US20040214856A1
(en)
*
|
2003-04-23 |
2004-10-28 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
US7145012B2
(en)
*
|
2003-04-23 |
2006-12-05 |
Pfizer Inc. |
Cannabinoid receptor ligands and uses thereof
|
US7268133B2
(en)
*
|
2003-04-23 |
2007-09-11 |
Pfizer, Inc. Patent Department |
Cannabinoid receptor ligands and uses thereof
|
US7141669B2
(en)
*
|
2003-04-23 |
2006-11-28 |
Pfizer Inc. |
Cannabiniod receptor ligands and uses thereof
|
JP4041153B2
(ja)
*
|
2003-05-07 |
2008-01-30 |
ファイザー・プロダクツ・インク |
カンナビノイド受容体リガンドとその使用
|
US20040224963A1
(en)
*
|
2003-05-09 |
2004-11-11 |
Pfizer Inc |
Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
|
JP4901474B2
(ja)
*
|
2003-05-30 |
2012-03-21 |
ランバクシー ラボラトリーズ リミテッド |
置換ピロール誘導体
|
US7232823B2
(en)
|
2003-06-09 |
2007-06-19 |
Pfizer, Inc. |
Cannabinoid receptor ligands and uses thereof
|
EP1641779A1
(de)
*
|
2003-06-18 |
2006-04-05 |
AstraZeneca AB |
2-substituierte 5, 6-diaryl-pyrazinderivative als cb1 modulator
|
US20040259887A1
(en)
*
|
2003-06-18 |
2004-12-23 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
GB0314057D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
GB0314261D0
(en)
*
|
2003-06-19 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
CA2528785A1
(en)
|
2003-06-20 |
2005-01-06 |
Matthias Heinrich Nettekoven |
2-amidobenzothiazoles as cb1 receptor inverse agonists
|
FR2856683A1
(fr)
*
|
2003-06-25 |
2004-12-31 |
Sanofi Synthelabo |
Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
ATE547404T1
(de)
|
2003-09-22 |
2012-03-15 |
Msd Kk |
Piperidinderivate
|
FR2861992B1
(fr)
*
|
2003-11-10 |
2007-07-20 |
Sanofi Synthelabo |
Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
|
AU2004299198A1
(en)
|
2003-12-08 |
2005-06-30 |
F. Hoffmann-La Roche Ag |
Novel thiazole derivates
|
TW200522944A
(en)
*
|
2003-12-23 |
2005-07-16 |
Lilly Co Eli |
CB1 modulator compounds
|
JP2007084437A
(ja)
*
|
2003-12-26 |
2007-04-05 |
Dai Ichi Seiyaku Co Ltd |
アミノアルキルピラゾール誘導体
|
FR2864958B1
(fr)
*
|
2004-01-12 |
2006-02-24 |
Sanofi Synthelabo |
Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.
|
CA2553970A1
(en)
|
2004-01-28 |
2005-08-18 |
F. Hoffmann-La Roche Ag |
Spiro-benzodioxoles and their use as cb1 antagonists
|
US7649002B2
(en)
|
2004-02-04 |
2010-01-19 |
Pfizer Inc |
(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
|
TW200533657A
(en)
*
|
2004-02-17 |
2005-10-16 |
Esteve Labor Dr |
Substituted pyrazoline compounds, their preparation and use as medicaments
|
US20090149463A1
(en)
*
|
2004-02-20 |
2009-06-11 |
Leifeng Cheng |
Therapeutic agents
|
WO2005080342A1
(en)
*
|
2004-02-24 |
2005-09-01 |
Glaxo Group Limited |
Pyridine derivatives and their use as cb2 receptor modulators
|
EP1574211A1
(de)
|
2004-03-09 |
2005-09-14 |
Inserm |
Verwendung von CB1-Rezeptor-Antagonisten zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankungen
|
US7262318B2
(en)
*
|
2004-03-10 |
2007-08-28 |
Pfizer, Inc. |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
FR2867685B1
(fr)
*
|
2004-03-17 |
2008-05-23 |
Sanofi Synthelabo |
Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement de la bronchite chronique et de la broncho-pneumopathie chronique obstructive
|
CN1938286A
(zh)
|
2004-03-29 |
2007-03-28 |
默克公司 |
作为11-β-羟甾类脱氢酶-1抑制剂的二芳基三唑
|
US20080125403A1
(en)
|
2004-04-02 |
2008-05-29 |
Merck & Co., Inc. |
Method of Treating Men with Metabolic and Anthropometric Disorders
|
JP4177435B2
(ja)
*
|
2004-04-03 |
2008-11-05 |
アストラゼネカ アクチボラグ |
治療薬
|
FR2869905B1
(fr)
*
|
2004-05-10 |
2008-09-05 |
Sanofi Synthelabo |
Procede de preparation d'ester de l'acide 1,5-diphenylpyrazole carboxylique.
|
BRPI0510679A
(pt)
|
2004-05-10 |
2007-12-26 |
Hoffmann La Roche |
compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação dos receptores de cb1 e utilização desses compostos
|
ITMI20041033A1
(it)
*
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Composti farmaceutici
|
TW200602314A
(en)
*
|
2004-05-28 |
2006-01-16 |
Tanabe Seiyaku Co |
A novel pyrrolidine compound and a process for preparing the same
|
DK1828167T3
(da)
*
|
2004-06-04 |
2014-10-20 |
Debiopharm Int Sa |
Acrylamidderivater som antibiotiske midler
|
UY28945A1
(es)
|
2004-06-09 |
2006-01-31 |
Glaxo Group Ltd |
Derivados de pirrolopiridina
|
US20050288340A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Pfizer Inc |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
WO2006025069A2
(en)
|
2004-07-12 |
2006-03-09 |
Cadila Healthcare Limited |
Tricyclic pyrazole derivatives as cannabinoid receptor modulators
|
US20060025448A1
(en)
|
2004-07-22 |
2006-02-02 |
Cadila Healthcare Limited |
Hair growth stimulators
|
CN101072769A
(zh)
*
|
2004-08-06 |
2007-11-14 |
第一制药株式会社 |
抗血小板药及其制造方法
|
CA2575736A1
(en)
|
2004-08-06 |
2006-02-16 |
Merck & Co., Inc. |
Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
|
WO2006014005A1
(ja)
*
|
2004-08-06 |
2006-02-09 |
Daiichi Pharmaceutical Co., Ltd. |
ピラゾール誘導体
|
GB0417910D0
(en)
|
2004-08-11 |
2004-09-15 |
Novartis Ag |
Organic compounds
|
AU2005272627A1
(en)
*
|
2004-08-13 |
2006-02-23 |
Amgen Inc. |
Substituted benzofused heterocycles
|
FR2875409B1
(fr)
*
|
2004-09-17 |
2010-05-07 |
Sanofi Aventis |
Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
|
EP1807070A1
(de)
*
|
2004-09-29 |
2007-07-18 |
Schering Corporation |
Kombinationen aus substituierten azetidinonen und cb1-antagonisten
|
ATE399156T1
(de)
|
2004-10-27 |
2008-07-15 |
Hoffmann La Roche |
Neue indol- oder benzimidazol-derivate
|
US8394765B2
(en)
*
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
WO2006052608A2
(en)
|
2004-11-01 |
2006-05-18 |
Amylin Pharmaceuticals, Inc. |
Treatment of obesity and related disorders
|
AU2005304039A1
(en)
|
2004-11-09 |
2006-05-18 |
F. Hoffmann-La Roche Ag |
Dibenzosuberone derivatives
|
CA2589483C
(en)
|
2004-12-03 |
2013-10-29 |
Schering Corporation |
Substituted piperazines as cb1 antagonists
|
FR2880023B1
(fr)
|
2004-12-23 |
2007-02-23 |
Sanofi Aventis Sa |
Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
|
EP1833802A2
(de)
*
|
2004-12-23 |
2007-09-19 |
AstraZeneca AB |
1,2-diphenyl-imidazolderivate und deren verwendung als cb1-rezeptorliganden
|
WO2006067443A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Astrazeneca Ab |
Therapeutic agents
|
US20080234323A1
(en)
*
|
2005-01-06 |
2008-09-25 |
Braj Bhushan Lohray |
Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride
|
DOP2006000010A
(es)
|
2005-01-10 |
2006-07-31 |
Arena Pharm Inc |
Procedimiento para preparar eteres aromáticos
|
CA2594488C
(en)
*
|
2005-01-10 |
2015-04-28 |
University Of Connecticut |
Novel heteropyrrole analogs acting on cannabinoid receptors
|
US8853205B2
(en)
|
2005-01-10 |
2014-10-07 |
University Of Connecticut |
Heteropyrrole analogs acting on cannabinoid receptors
|
FR2880890B1
(fr)
*
|
2005-01-19 |
2007-03-30 |
Sanofi Aventis Sa |
Derives de n-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide, leur preparation et leur application en therapeutique
|
PA8660701A1
(es)
|
2005-02-04 |
2006-09-22 |
Pfizer Prod Inc |
Agonistas de pyy y sus usos
|
FR2881744B1
(fr)
*
|
2005-02-09 |
2007-04-27 |
Sanofi Aventis Sa |
Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
|
FR2882054B1
(fr)
*
|
2005-02-17 |
2007-04-13 |
Sanofi Aventis Sa |
Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
|
FR2882263B1
(fr)
*
|
2005-02-23 |
2007-04-06 |
Sanofi Aventis Sa |
Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales
|
FR2882931B1
(fr)
*
|
2005-03-14 |
2007-05-18 |
Sanofi Aventis Sa |
Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique
|
DK1868999T3
(da)
|
2005-04-06 |
2009-08-17 |
Hoffmann La Roche |
Pyridin-3-carboxamidderivater som omvendte CB1-agonister
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
WO2006129193A2
(en)
*
|
2005-05-27 |
2006-12-07 |
Pfizer Products Inc. |
Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
|
US8138206B2
(en)
|
2005-05-30 |
2012-03-20 |
Msd. K.K. |
Piperidine derivative
|
US7923465B2
(en)
|
2005-06-02 |
2011-04-12 |
Glenmark Pharmaceuticals S.A. |
Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
KR100970055B1
(ko)
*
|
2005-06-22 |
2010-07-16 |
에프. 호프만-라 로슈 아게 |
6-(플루오로-벤조[1,3]디옥솔일)-모폴린-4-일-메탄온 및cb1 리간드로서 그의 용도
|
FR2887550A1
(fr)
*
|
2005-06-24 |
2006-12-29 |
Sanofi Aventis Sa |
Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique
|
FR2887548B1
(fr)
*
|
2005-06-27 |
2007-09-21 |
Sanofi Aventis Sa |
Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique
|
NZ564759A
(en)
|
2005-06-30 |
2011-08-26 |
Prosidion Ltd |
GPCR agonists
|
CA2614528A1
(en)
*
|
2005-07-11 |
2007-01-18 |
N.V. Organon |
Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)
|
US7829581B2
(en)
*
|
2005-07-15 |
2010-11-09 |
Laboratorios Del Dr. Esteve, S.A. |
Prodrugs of pyrazoline compounds, their preparation and use as medicaments
|
WO2007009693A1
(en)
*
|
2005-07-15 |
2007-01-25 |
Laboratorios Del Dr.Esteve, S.A |
Combination of a substituted pyrazoline compound and a drug used in food-related disorders
|
EP1743892A1
(de)
*
|
2005-07-15 |
2007-01-17 |
Laboratorios del Dr. Esteve S.A. |
Substituierte Pyrazolin Verbindungen, deren Herstellung und Verwendung als Medikament
|
ES2337005B1
(es)
*
|
2005-07-15 |
2011-01-10 |
Laboratorios Del Dr. Esteve, S.A. |
Compuestos de pirazolina azepan o azocansustituidos, su preparacion ysu uso como medicamentos.
|
EP1743636A1
(de)
*
|
2005-07-15 |
2007-01-17 |
Laboratorios Del Dr. Esteve, S.A. |
Kombination eines substituierten Pyrazolins und eines bei Essstörungen verwendeten Mittels
|
ES2326461B1
(es)
*
|
2005-07-15 |
2010-04-19 |
Laboratorios Del Dr. Esteve, S.A. |
Polimorfo de n-priperidinil-5-(4-clorofenil)-1-(2,4-dicloforenil)-4,5-dihidro-1h-pirazol-3-carboxamida y su uso como modulador de receptores de cannabinoides.
|
EP1743637A1
(de)
|
2005-07-15 |
2007-01-17 |
Laboratorios Del Dr. Esteve, S.A. |
Verwendung substituierter Pyrazolinderivate und Kombinationen davon zur Behandlung des metabolischen Syndroms
|
EP1757588A1
(de)
*
|
2005-07-29 |
2007-02-28 |
Laboratorios Del Dr. Esteve, S.A. |
Polymorph des N-Piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamids und seine Verwendung als Cannabinoid-Rezeptor-Modulator
|
EP1743890A1
(de)
*
|
2005-07-15 |
2007-01-17 |
Laboratorios Del Dr. Esteve, S.A. |
4,5-Dihydro-1H-Pyrazol-Derivative, Verfahren zur Herstellung und ihre Verwendung als Medikamente.
|
GB0514739D0
(en)
*
|
2005-07-19 |
2005-08-24 |
Astrazeneca Ab |
Therapeutic agents
|
GB0514738D0
(en)
*
|
2005-07-19 |
2005-08-24 |
Astrazeneca Ab |
Therapeutic agents
|
EP1752149A1
(de)
|
2005-07-29 |
2007-02-14 |
Laboratorios Del Dr. Esteve, S.A. |
CB1 Antagonists oder umgekehrte Agonists als therapeutische Mittel zur Behandlung der Entzündung mit einbeziehenden Genausdruck
|
CA2617654A1
(en)
*
|
2005-08-04 |
2007-02-08 |
Pfizer Limited |
Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
|
CA2518579A1
(en)
*
|
2005-08-05 |
2007-02-05 |
University Technologies International Inc. |
Method for appetite suppression
|
US20080221097A1
(en)
*
|
2005-08-09 |
2008-09-11 |
Glaxo Group Limited |
Imidazopyridine Derivatives as Cannabinoid Receptor Ligands
|
WO2007018248A1
(ja)
|
2005-08-10 |
2007-02-15 |
Banyu Pharmaceutical Co., Ltd. |
ピリドン化合物
|
EP2330125A3
(de)
|
2005-08-11 |
2012-12-12 |
Amylin Pharmaceuticals, Inc. |
Hybridpolypeptide mit auswählbaren Eigenschaften
|
AU2006279680B2
(en)
|
2005-08-11 |
2012-12-06 |
Amylin Pharmaceuticals, Llc |
Hybrid polypeptides with selectable properties
|
AU2006280511A1
(en)
*
|
2005-08-12 |
2007-02-22 |
Astrazeneca Ab |
Process
|
EP1757290A1
(de)
*
|
2005-08-16 |
2007-02-28 |
Zentaris GmbH |
Triazolderivate als Liganden der Wachstumshormonrezeptoren
|
US7875633B2
(en)
|
2005-08-24 |
2011-01-25 |
Banyu Pharmaceutical Co., Ltd. |
Phenylpyridone derivative
|
WO2007029847A1
(ja)
|
2005-09-07 |
2007-03-15 |
Banyu Pharmaceutical Co., Ltd. |
二環性芳香族置換ピリドン誘導体
|
GB0518819D0
(en)
*
|
2005-09-15 |
2005-10-26 |
Astrazeneca Ab |
Therapeutic agents
|
CN101312952B
(zh)
*
|
2005-09-23 |
2012-12-26 |
詹森药业有限公司 |
四氢-环戊二烯并吡唑大麻素调节剂
|
JP4879988B2
(ja)
|
2005-09-29 |
2012-02-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
|
NZ566660A
(en)
*
|
2005-09-30 |
2010-03-26 |
Banyu Pharma Co Ltd |
Aryl-substituted nitrogen-containing heterocyclic compound
|
AR056560A1
(es)
*
|
2005-10-06 |
2007-10-10 |
Astrazeneca Ab |
Pirrolopiridinonas como moduladores cb1
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
WO2007049798A1
(ja)
|
2005-10-27 |
2007-05-03 |
Banyu Pharmaceutical Co., Ltd. |
新規ベンゾオキサチイン誘導体
|
AU2006313430B2
(en)
*
|
2005-11-08 |
2012-09-06 |
Ranbaxy Laboratories Limited |
Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
AU2006312557B2
(en)
|
2005-11-10 |
2011-12-08 |
Msd K.K. |
Aza-substituted spiro derivative
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
US20090156578A1
(en)
*
|
2005-12-05 |
2009-06-18 |
PAULS Henry |
3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
|
FR2894579B1
(fr)
*
|
2005-12-12 |
2008-01-18 |
Sanofi Aventis Sa |
Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
|
FR2894578B1
(fr)
|
2005-12-12 |
2008-02-01 |
Sanofi Aventis Sa |
Derives heterocycliques, leur preparation et leur application en therapeutique.
|
EP1801098A1
(de)
|
2005-12-16 |
2007-06-27 |
Merck Sante |
2-Adamantylharnstoff Derivative als selektive 11B-HSD1 Inhibitoren
|
CN100999517B
(zh)
*
|
2006-01-11 |
2010-12-15 |
北京摩力克科技有限公司 |
吡唑甲酰胺衍生物,药物组合物和其制备方法
|
CA2637565A1
(en)
|
2006-01-18 |
2007-07-26 |
Schering Corporation |
Cannibinoid receptor modulators
|
EA200801738A1
(ru)
*
|
2006-02-23 |
2008-12-30 |
Пфайзер Лимитед |
Пиперидиноилпирролидиновые агонисты меланокортинового рецептора 4 типа
|
AU2007226673A1
(en)
*
|
2006-03-10 |
2007-09-20 |
Jenrin Discovery |
Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
|
WO2008020314A2
(en)
*
|
2006-03-14 |
2008-02-21 |
Ranbaxy Laboratories Limited |
Statin stabilizing dosage formulations
|
WO2007121466A2
(en)
*
|
2006-04-18 |
2007-10-25 |
Dr. Reddy's Laboratories Ltd. |
Process for preparing rimonabant
|
US20070287734A1
(en)
*
|
2006-06-09 |
2007-12-13 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
|
US7629346B2
(en)
|
2006-06-19 |
2009-12-08 |
Hoffmann-La Roche Inc. |
Pyrazinecarboxamide derivatives as CB1 antagonists
|
WO2008038143A2
(en)
*
|
2006-06-22 |
2008-04-03 |
Medichem, S.A. |
Novel solid forms of rimonabant and synthetic processes for their preparation
|
US7803799B2
(en)
*
|
2006-07-07 |
2010-09-28 |
National Health Research Institutes |
Selenophene compounds
|
ATE469129T1
(de)
*
|
2006-07-11 |
2010-06-15 |
Sanofi Aventis |
N-ä(1,5-diphenyl-1h-pyrazol-3- yl)methylüsulfonamid-derivate antagonisten der cb1 rezeptoren der cannabinoide
|
AR063469A1
(es)
*
|
2006-07-14 |
2009-01-28 |
Ranbaxy Lab Ltd |
Formas polimorficas de ácido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3, 5-dihidroxi-heptanoico, sal hemicalcio, metodos de preparacion de las mismas, una composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades
|
EP2054422B1
(de)
|
2006-07-20 |
2017-06-14 |
Debiopharm International SA |
Acrylamidderivate als fab-i-inhibitoren
|
US20100076022A1
(en)
*
|
2006-09-01 |
2010-03-25 |
Hetero Drugs Limited |
Novel polymorphs of rimonabant
|
BRPI0716134A2
(pt)
|
2006-09-07 |
2013-09-17 |
Nycomed Gmbh |
tratamento de combinaÇço para diabetes mellitus
|
EP2061783A2
(de)
*
|
2006-09-11 |
2009-05-27 |
Hetero Drugs Limited |
Verbessertes verfahren für rimonabant
|
US7781593B2
(en)
|
2006-09-14 |
2010-08-24 |
Hoffmann-La Roche Inc. |
5-phenyl-nicotinamide derivatives
|
WO2008035023A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Cipla Limited |
Polymorphs of rimonabant
|
EP2946778A1
(de)
|
2006-09-22 |
2015-11-25 |
Merck Sharp & Dohme Corp. |
Behandlungsverfahren mit verwendung von fettsäuresyntheseinhibitoren
|
AU2007301126A1
(en)
|
2006-09-28 |
2008-04-03 |
Banyu Pharmaceutical Co., Ltd. |
Diaryl ketimine derivative
|
TWI339205B
(en)
*
|
2006-10-02 |
2011-03-21 |
Nat Health Research Institutes |
Pyrazole compounds and pharmaceutical composition
|
TWI408136B
(zh)
*
|
2006-10-02 |
2013-09-11 |
Nat Health Research Institutes |
噻吩化合物及其醫藥組成物
|
US20080108643A1
(en)
*
|
2006-11-03 |
2008-05-08 |
Forest Laboratories Holdings Limited |
Method for treating autism
|
KR20090064478A
(ko)
|
2006-11-13 |
2009-06-18 |
화이자 프로덕츠 인크. |
디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도
|
FR2909090B1
(fr)
|
2006-11-23 |
2009-01-09 |
Sanofi Aventis Sa |
Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique.
|
WO2008062480A2
(en)
*
|
2006-11-24 |
2008-05-29 |
Ind-Swift Laboratories Limited |
An improved process for the preparation of rimonabant
|
CN101663262B
(zh)
|
2006-12-01 |
2014-03-26 |
百时美施贵宝公司 |
用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
|
JP5437812B2
(ja)
*
|
2006-12-18 |
2014-03-12 |
7ティーエム ファーマ エイ/エス |
Cb1受容体モジュレーター
|
EP1935420A1
(de)
|
2006-12-21 |
2008-06-25 |
Merck Sante |
2-Adamantyl-Butyramid Derivate als selektive 11Beta-HSD1 Inhibitoren
|
CL2008000017A1
(es)
|
2007-01-04 |
2008-08-01 |
Prosidion Ltd |
Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
|
WO2008081208A1
(en)
|
2007-01-04 |
2008-07-10 |
Prosidion Limited |
Piperidine gpcr agonists
|
PE20081659A1
(es)
|
2007-01-04 |
2008-10-24 |
Prosidion Ltd |
Agonistas de gpcr
|
GB0700122D0
(en)
|
2007-01-04 |
2007-02-14 |
Prosidion Ltd |
GPCR agonists
|
BRPI0806498A2
(pt)
|
2007-01-04 |
2014-04-22 |
Prosidion Ltd |
Agonistas gpcr piperidina
|
US20080182877A1
(en)
*
|
2007-01-05 |
2008-07-31 |
Westheim Raymond J H |
Rimonabant forms and methods of making the same
|
FR2911136B1
(fr)
|
2007-01-05 |
2009-02-20 |
Sanofi Aventis Sa |
Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
|
WO2008088900A2
(en)
*
|
2007-01-18 |
2008-07-24 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic forms of rimonabant base and processes for preparation thereof
|
TW200848039A
(en)
*
|
2007-02-09 |
2008-12-16 |
Astrazeneca Ab |
Pharmaceutical compositions
|
GB0702862D0
(en)
*
|
2007-02-14 |
2007-03-28 |
Univ Aberdeen |
Therapeutic compounds
|
EP2125802A4
(de)
*
|
2007-02-16 |
2014-08-20 |
Debiopharm Int Sa |
Salze, prodrugs und polymorphe von fab-i-inhibitoren
|
US20080221057A1
(en)
*
|
2007-02-16 |
2008-09-11 |
Wyeth |
Secreted protein ccdc80 regulates adipocyte differentiation
|
WO2008102367A1
(en)
*
|
2007-02-19 |
2008-08-28 |
Darmesh Mahendrabhai Shah |
Process for preparation of pyrazole derivatives
|
WO2008101860A1
(en)
*
|
2007-02-20 |
2008-08-28 |
Sandoz Ag |
Novel process for the preparation of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-(piperidin-1-yl)pyrazole-3-carboxamide
|
JP5319518B2
(ja)
|
2007-04-02 |
2013-10-16 |
Msd株式会社 |
インドールジオン誘導体
|
US7705024B2
(en)
*
|
2007-04-12 |
2010-04-27 |
National Health Research Institutes |
Oxadiazole compounds
|
US20100197564A1
(en)
*
|
2007-04-19 |
2010-08-05 |
Schering Corporation |
Diaryl morpholines as cb1 modulators
|
CN101314591B
(zh)
*
|
2007-05-30 |
2010-09-29 |
上海阳帆医药科技有限公司 |
吡唑类高选择性大麻受体-1拮抗剂和/或反向激动剂
|
MX2009013354A
(es)
|
2007-06-04 |
2010-07-06 |
Univ Ben Gurion |
Compuestos de triarilo y composiciones que los contienen.
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
WO2008151257A2
(en)
|
2007-06-04 |
2008-12-11 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
MX2009013215A
(es)
*
|
2007-06-15 |
2010-01-25 |
Irm Llc |
Compuestos y composiciones como inhibidores de itpkb.
|
RU2010102478A
(ru)
*
|
2007-06-28 |
2011-08-10 |
Интэрвэт Интэрнэшнл Б.Ф. (NL) |
Замещенные пиперазины как антагонисты св1
|
WO2009005671A2
(en)
*
|
2007-06-28 |
2009-01-08 |
Schering Corporation |
Substituted piperazines as cb1 antagonists
|
US8338623B2
(en)
*
|
2007-07-09 |
2012-12-25 |
Abbvie Inc. |
Compounds as cannabinoid receptor ligands
|
FR2919184A1
(fr)
*
|
2007-07-26 |
2009-01-30 |
Sanofi Aventis Sa |
L'acide 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4- methylpyrazole-3-carboxylique, ses esters, ses sels pharmaceutiquement acceptables et leurs solvates pour leur utilisation comme medicament.
|
EP2176208B1
(de)
*
|
2007-07-30 |
2015-01-21 |
Zynerba Pharmaceuticals, Inc. |
Prodgrugs von cannabidiol, zusammensetzungen mit prodgrugs von cannabidiol und verfahren zu ihrer verwendung
|
US8133904B2
(en)
*
|
2007-09-07 |
2012-03-13 |
Jenrin Discovery, Inc. |
Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
|
WO2009063495A2
(en)
*
|
2007-09-20 |
2009-05-22 |
Cadila Healthcare Limited |
Substituted indole and its derivatives as cannabinoid modulators
|
GB0720389D0
(en)
|
2007-10-18 |
2008-11-12 |
Prosidion Ltd |
G-Protein Coupled Receptor Agonists
|
GB0720390D0
(en)
|
2007-10-18 |
2007-11-28 |
Prosidion Ltd |
G-Protein coupled receptor agonists
|
US20100323955A1
(en)
*
|
2007-11-14 |
2010-12-23 |
Amylin Pharmaceuticals, Inc. |
Methods for treating obesity and obesity related diseases and disorders
|
US8829043B2
(en)
|
2008-02-08 |
2014-09-09 |
Nektar Therapeutics |
Oligome-cannabinoid conjugates
|
US20090247619A1
(en)
*
|
2008-03-06 |
2009-10-01 |
University Of Kentucky |
Cannabinoid-Containing Compositions and Methods for Their Use
|
US20110015181A1
(en)
|
2008-03-06 |
2011-01-20 |
Makoto Ando |
Alkylaminopyridine derivative
|
DE102008015033A1
(de)
|
2008-03-17 |
2009-09-24 |
Aicuris Gmbh & Co. Kg |
Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
|
EP2103602A1
(de)
|
2008-03-17 |
2009-09-23 |
AEterna Zentaris GmbH |
Neuartige 1,2,4-Triazol-Derivate und Herstellungsverfahren dafür
|
DE102008015032A1
(de)
|
2008-03-17 |
2009-09-24 |
Aicuris Gmbh & Co. Kg |
Substituierte Pyrazolamide und ihre Verwendung
|
US20110015198A1
(en)
|
2008-03-28 |
2011-01-20 |
Banyu Pharmaceutical Co., Inc. |
Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
|
EP2110374A1
(de)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofuran, Benzothiophen, Benzothiazolderivate als FXR-Modulatoren
|
EP2328910B1
(de)
|
2008-06-04 |
2014-08-06 |
Synergy Pharmaceuticals Inc. |
Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
|
CA2727914A1
(en)
|
2008-06-19 |
2009-12-23 |
Banyu Pharmaceutical Co., Ltd. |
Spirodiamine-diaryl ketoxime derivative technical field
|
AU2009270833B2
(en)
|
2008-07-16 |
2015-02-19 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
EP2151234A1
(de)
*
|
2008-07-28 |
2010-02-10 |
Laboratorios Del. Dr. Esteve, S.A. |
Pharmazeutische Formulierung mit einer CB1-Rezeptorverbindung in einer festen Lösung und/oder festen Dispersion
|
AU2009277736A1
(en)
|
2008-07-30 |
2010-02-04 |
Banyu Pharmaceutical Co., Ltd. |
(5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
|
AU2009278838B2
(en)
*
|
2008-08-06 |
2013-07-25 |
Pfizer Limited |
Diazepine and diazocane compounds as MC4 agonists
|
CA2741125A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
US8592457B2
(en)
|
2008-10-30 |
2013-11-26 |
Merck Sharp & Dohme Corp. |
Isonicotinamide orexin receptor antagonists
|
WO2010051206A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
TWI434686B
(zh)
*
|
2008-11-03 |
2014-04-21 |
Nat Health Research Institutes |
咪唑-4-酮及咪唑-4-硫酮化合物
|
WO2010056717A1
(en)
|
2008-11-17 |
2010-05-20 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic amines for the treatment of diabetes
|
EP2379562A1
(de)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Bicyclische pyranonderivate als agonisten am nicotinsäurerezeptor
|
EP2379547A1
(de)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Pyridopyrimidinderivate und verfahren zu deren anwendung
|
DE102008062863A1
(de)
|
2008-12-17 |
2010-06-24 |
Aicuris Gmbh & Co. Kg |
Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
|
DE102008062878A1
(de)
|
2008-12-17 |
2010-06-24 |
Aicuris Gmbh & Co. Kg |
Substituierte Furancarboxamide und ihre Verwendung
|
WO2010079241A1
(es)
|
2009-01-12 |
2010-07-15 |
Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion |
Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
|
KR101070176B1
(ko)
*
|
2009-01-13 |
2011-10-05 |
(주)에스에이치제약 |
Cb1에 길항 활성을 갖는 1h-파이라졸-3-아마이드계 화합물 또는 1h-파이라졸-3-옥소아세트아마이드계 화학물 유도체 및 이를 포함하는 약제학적 조성물
|
EP2395987A1
(de)
|
2009-02-12 |
2011-12-21 |
Coöperatieve Mirzorg U.A., Arnhem |
Verwendung einer kombination aus diazoxid und metformin zur behandlung von adipositas bzw. erkrankungen im zusammenhang mit adipositas
|
US10053444B2
(en)
|
2009-02-19 |
2018-08-21 |
University Of Connecticut |
Cannabinergic nitrate esters and related analogs
|
US20120220567A1
(en)
|
2009-07-23 |
2012-08-30 |
Shipps Jr Gerald W |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
DE102009036604A1
(de)
|
2009-07-30 |
2011-02-03 |
Aicuris Gmbh & Co. Kg |
Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung
|
US8217038B2
(en)
|
2009-10-07 |
2012-07-10 |
Jenrin Discovery, Inc. |
Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
|
ES2527179T3
(es)
|
2009-11-02 |
2015-01-21 |
Pfizer Inc. |
Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
|
JP2013510834A
(ja)
|
2009-11-16 |
2013-03-28 |
メリテク |
[1,5]‐ジアゾシン誘導体
|
EP2521721B1
(de)
*
|
2009-12-30 |
2014-10-01 |
Shanghai Fochon Pharmaceutical Co. Ltd |
3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazin-derivate als dipeptidyl-peptidase iv (dpp iv)-hemmer
|
CA2786994C
(en)
|
2010-01-27 |
2018-01-16 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
|
CA2786314A1
(en)
|
2010-02-25 |
2011-09-01 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
US8785634B2
(en)
|
2010-04-26 |
2014-07-22 |
Merck Sharp & Dohme Corp |
Spiropiperidine prolylcarboxypeptidase inhibitors
|
US9365539B2
(en)
|
2010-05-11 |
2016-06-14 |
Merck Sharp & Dohme Corp. |
Prolylcarboxypeptidase inhibitors
|
WO2011141848A1
(en)
|
2010-05-11 |
2011-11-17 |
Pfizer Inc. |
Morpholine compounds as mineralocorticoid receptor antagonists
|
WO2011156246A1
(en)
|
2010-06-11 |
2011-12-15 |
Merck Sharp & Dohme Corp. |
Novel prolylcarboxypeptidase inhibitors
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
EP2431035A1
(de)
|
2010-09-16 |
2012-03-21 |
Æterna Zentaris GmbH |
Neue Triazolderivate mit verbesserter Rezeptoraktivität und Bioverfügbarkeitseigenschaften als Ghrelin-Antagonisten der Wachstumshormon-Sekretagogum-Rezeptoren
|
WO2012040279A1
(en)
|
2010-09-22 |
2012-03-29 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
US8410107B2
(en)
|
2010-10-15 |
2013-04-02 |
Hoffmann-La Roche Inc. |
N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
|
US8669254B2
(en)
|
2010-12-15 |
2014-03-11 |
Hoffman-La Roche Inc. |
Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
|
PE20140859A1
(es)
|
2011-02-25 |
2014-07-25 |
Merck Sharp & Dohme |
Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos
|
CN102206182B
(zh)
*
|
2011-04-11 |
2013-03-13 |
中国药科大学 |
盐酸利莫那班的合成方法
|
CN102250006B
(zh)
*
|
2011-05-12 |
2014-03-05 |
范如霖 |
3-吡唑羧酸酰胺类化合物、其制备方法及其在制备作为cb1受体抑制剂药物中的应用
|
US9133128B2
(en)
|
2011-06-17 |
2015-09-15 |
Research Triangle Institute |
Pyrazole derivatives as cannabinoid receptor 1 antagonists
|
AR087701A1
(es)
|
2011-08-31 |
2014-04-09 |
Japan Tobacco Inc |
Derivados de pirazol con actividad inhibidora de sglt1
|
EP2757886A1
(de)
|
2011-09-23 |
2014-07-30 |
Bayer Intellectual Property GmbH |
Verwendung 4-substituierter 1-phenyl-pyrazol-3-carbonsäurederivate als wirkstoffe gegen abiotischen pflanzenstress
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
DE102011055815A1
(de)
|
2011-11-29 |
2013-05-29 |
Aicuris Gmbh & Co. Kg |
Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
|
KR20140096391A
(ko)
|
2011-11-30 |
2014-08-05 |
바이엘 인텔렉쳐 프로퍼티 게엠베하 |
살진균성 n-바이시클로알킬 및 n-트리시클로알킬 피라졸-4-(티오)카르복사미드 유도체
|
IN2014KN02915A
(de)
|
2012-06-19 |
2015-05-08 |
Debiopharm Int Sa |
|
BR112015002080A2
(pt)
|
2012-08-02 |
2017-07-04 |
Merck Sharp & Dohme |
composto, composição farmacêutica, uso de um composto, e, método de tratamento ou de prevenção de um transtorno, de uma condição ou de uma doença
|
DE102012016908A1
(de)
|
2012-08-17 |
2014-02-20 |
Aicuris Gmbh & Co. Kg |
Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
|
CA2922849A1
(en)
|
2012-08-31 |
2014-03-06 |
Ixchel Pharma, Llc |
Agents useful for treating obesity, diabetes and related disorders
|
NZ746490A
(en)
|
2012-10-02 |
2018-12-21 |
Bayer Cropscience Ag |
Heterocyclic compounds as pesticides
|
JPWO2014069554A1
(ja)
*
|
2012-10-31 |
2016-09-08 |
東レ株式会社 |
キヌクリジンアミド誘導体及びその医薬用途
|
EP2958562A4
(de)
|
2013-02-22 |
2016-08-10 |
Merck Sharp & Dohme |
Antidiabetische bicyclische verbindungen
|
US9650375B2
(en)
|
2013-03-14 |
2017-05-16 |
Merck Sharp & Dohme Corp. |
Indole derivatives useful as anti-diabetic agents
|
EP2968439A2
(de)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Zusammensetzungen zur behandlung von magen-darm-störungen
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
WO2014174457A1
(en)
|
2013-04-23 |
2014-10-30 |
Council Of Scientific & Industrial Research |
Pyrazole carboxylic acid analogues as anti-mycobacterial drug candidates
|
US10011637B2
(en)
|
2013-06-05 |
2018-07-03 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase C, method of making and using same
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
AU2014347668A1
(en)
|
2013-11-05 |
2016-05-19 |
Ben-Gurion University Of The Negev Research And Development Authority |
Compounds for the treatment of diabetes and disease complications arising from same
|
RU2705800C2
(ru)
*
|
2014-06-06 |
2019-11-12 |
Рисерч Трайэнгл Инститьют |
Агонисты рецептора апелина (apj) и их применение
|
BR112017003745A2
(pt)
|
2014-08-29 |
2017-12-05 |
Tes Pharma S R L |
inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
|
NZ734220A
(en)
|
2015-01-06 |
2022-01-28 |
Arena Pharm Inc |
Methods of treating conditions related to the s1p1 receptor
|
CN106279029A
(zh)
*
|
2015-05-21 |
2017-01-04 |
中国人民解放军军事医学科学院毒物药物研究所 |
4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
|
MA42807A
(fr)
|
2015-06-22 |
2018-07-25 |
Arena Pharm Inc |
Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
|
CN105061315B
(zh)
*
|
2015-08-06 |
2017-10-24 |
大连理工大学 |
一类1,5‑二苯基吡唑‑3‑羧酸类化合物及其应用
|
WO2017100558A1
(en)
|
2015-12-09 |
2017-06-15 |
Research Triangle Institute |
Improved apelin receptor (apj) agonists and uses thereof
|
TN2018000293A1
(en)
|
2016-02-26 |
2020-01-16 |
Debiopharm Int Sa |
Medicament for treatment of diabetic foot infections
|
MA46540A
(fr)
|
2016-10-12 |
2019-08-21 |
Res Triangle Inst |
Agonistes du récepteur de l'apéline (apj) hétérocyclique et leurs utilisations
|
TWI767945B
(zh)
|
2016-10-14 |
2022-06-21 |
義大利商Tes製藥(股份)責任有限公司 |
α-胺基-β-羧基己二烯二酸半醛去羧酶之抑制劑
|
US11111698B2
(en)
|
2016-12-05 |
2021-09-07 |
Endura Products, Llc |
Multipoint lock
|
EP3551176A4
(de)
|
2016-12-06 |
2020-06-24 |
Merck Sharp & Dohme Corp. |
Antidiabetische heterocyclische verbindungen
|
KR20190116416A
(ko)
|
2017-02-16 |
2019-10-14 |
아레나 파마슈티칼스, 인크. |
원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
|
KR101877002B1
(ko)
*
|
2017-03-06 |
2018-07-12 |
서울대학교 산학협력단 |
피라졸 유도체를 유효성분으로 함유하는 소양증의 예방 또는 치료용 약학적 조성물 및 이를 검출하기 위한 스크리닝 방법
|
TWI805699B
(zh)
|
2018-03-01 |
2023-06-21 |
日商日本煙草產業股份有限公司 |
甲基內醯胺環化合物及其用途
|
SG11202009179TA
(en)
|
2018-04-04 |
2020-10-29 |
Japan Tobacco Inc |
Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
|
SG11202104550WA
(en)
|
2018-11-20 |
2021-05-28 |
Tes Pharma S R L |
INHIBITORS OF a-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
|
US11098029B2
(en)
|
2019-02-13 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
WO2021026047A1
(en)
|
2019-08-08 |
2021-02-11 |
Merck Sharp & Dohme Corp. |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
US11091447B2
(en)
|
2020-01-03 |
2021-08-17 |
Berg Llc |
UBE2K modulators and methods for their use
|
CA3125847A1
(en)
|
2020-07-27 |
2022-01-27 |
Makscientific, Llc |
Process for making biologically active compounds and intermediates thereof
|
EP4200295A1
(de)
|
2020-08-18 |
2023-06-28 |
Merck Sharp & Dohme LLC |
Bicycloheptanpyrrolidinorexinrezeptoragonisten
|